Brand Intelligence Graph
Company Overview
About Aerska Therapeutics
Aerska Therapeutics is developing a brain-shuttle RNAi (RNA interference) platform for CNS gene silencing — specifically targeting the genetic forms of Alzheimer's disease and Parkinson's disease caused by dominant mutations that can be silenced by RNA therapeutics. The company raised $39 million in February 2026, doubling its prior $21 million Series A round, led by ex-AstraZeneca neuroscience executives who validated both the science and the commercial opportunity.
Business Model & Competitive Advantage
The blood-brain barrier (BBB) is the primary obstacle to CNS gene silencing: RNA therapeutics that work in peripheral tissues cannot efficiently reach the brain because the BBB prevents most molecules from crossing from blood to brain tissue. Aerska's brain-shuttle technology uses receptor-mediated transcytosis — hijacking the brain's natural nutrient transport mechanisms — to deliver RNAi payloads to specific CNS targets without requiring intrathecal injection or viral vectors.
Competitive Landscape 2025–2026
Genetic forms of Alzheimer's (APOE4, PSEN1/2 mutations) and Parkinson's (LRRK2, SNCA mutations) are among the most genetically validated drug targets in neuroscience: the mutations that cause these diseases are known, the proteins they encode are well-characterized, and reducing their expression is the mechanistically justified therapeutic strategy. Aerska's focus on genetic forms provides a biomarker-selected patient population where clinical success probability is meaningfully higher than in unselected Alzheimer's and Parkinson's populations.
Key Differentiators
Emerging Innovator
Aerska Therapeutics is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
DNAnexus
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a
Saluda Medical
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US oper
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
Schrödinger
Schrödinger was founded in 1990 by Richard Friesner and David Pearlman in New York City, building physics-based computational methods for molecular simulation. For over 30 years the company has develo
Compare Aerska Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Aerska Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Aerska Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Aerska Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →